Key facts
- It has raised $16.1M; the latest was Early Stage VC ($10.0M) in Jun 2024.
- Notable investors include MassChallenge, Khosla Ventures, Innovation Authority, StartLife, DIVEdigital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Enzymit
- ·The full record, as it builds
Funding rounds
No funding rounds for Enzymit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enzymit
Developer of a discovery platform designed to create new-to-nature enzymes. The company uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, food tech, health, and biodefense, enabling global manufacturers to streamline production processes, reduce costs, and promote sustainability.
- Sector
- Business Products and Services (B2B)
- HQ
- Rehovot, Israel
- Founded
- 2020
- Employees
- 22
- Website
- enzymit.com/
- Ownership
- Privately Held (backing)
Enzymit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enzymit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enzymit in its N-PORT filings yet. We sweep new filings monthly.